Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release oral formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts on the central nervous system to relieve pain. It is prescribed for several recognized pain‑related conditions: - Chronic low back pain: provides sustained relief of moderate to severe pain. - Osteoarthritis pain: improves functional ability and reduces pain intensity. - Neuropathic pain associated with diabetic peripheral neuropathy: alleviates burning and shooting sensations. - Cancer‑related chronic pain: contributes to overall pain control as part of multimodal therapy. - Post‑surgical chronic pain (when pain persists beyond the usual healing period): helps manage lingering moderate to severe pain.

Adverse reactions may occur with Palexia Retard and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Dizziness: feeling light‑headed or unsteady. - Somnolence: increased sleepiness. - Headache: mild to moderate head pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Seizures: convulsive episodes, especially at high doses. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of misuse with prolonged use. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Palexia Retard, clinicians should consider several safety aspects: - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic function: monitor for accumulation in liver disease. - Screen for respiratory disorders: patients with COPD or sleep apnea are at higher risk of respiratory depression. - Review concomitant CNS depressants: avoid additive sedation with benzodiazepines or alcohol. - Pregnancy and lactation: use only if clearly needed; discuss risks with the patient. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Palexia Retard can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - CNS depressants (e.g., benzodiazepines, barbiturates): additive respiratory depression. - CYP2D6 inhibitors (e.g., quinidine, fluoxetine): increased tapentadol plasma levels.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., tramadol, SSRIs): potential for serotonin syndrome. - Antihistamines with sedative properties: enhanced drowsiness. - Diuretics: may exacerbate hypotension. - Anticonvulsants: possible reduction in seizure‑threshold protection. - Alcohol: increased risk of sedation and respiratory depression.